Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 4/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11587907 | 0.88 | NPC1 (0.47) | CYP1A2CYP3A4CYP2C19PDK1MAPT | |
| SCHEMBL11341140 | 0.86 | KMT2A (0.59) | CYP1A2CYP3A4CYP2C19MAPTNPC1 | |
| SCHEMBL11338493 | 0.83 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2C19PDK1MAPT | |
| SCHEMBL11100119 | 0.82 | NPC1 (0.58) | CYP3A4MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5351987 | 0.81 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2C19PDK1MAPT | |
| SCHEMBL11335893 | 0.80 | RAB9A (0.51) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3242801 | 0.80 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2C19PDK1MAPT | |
| SCHEMBL202215 | 0.80 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2C19PDK1MAPT | |
| SCHEMBL7542512 | 0.80 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2C19PDK1MAPT | |
| SCHEMBL16150961 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C19PDK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11209582-B2 | Composition, curable composition, cured film, near infrared cut filter, infrared transmitting filter, solid image pickup element, infrared sensor, and camera module | FUJIFILM CORPORATION (JP) | 2021-12-28 | — | — | US | disclosed |
| US-20170174869-A1 | COMPOSITION, METHOD OF MANUFACTURING COMPOSITION, CURABLE COMPOSITION, CURED FILM, NEAR-INFRARED CUT FILTER, SOLID-STATE IMAGING DEVICE, INFRARED SENSOR, AND CAMERA MODULE | FUJIFILM CORPORATION (JP) | 2017-06-22 | — | — | US | disclosed |
| US-9434720-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DIRMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8883050-B2 | Curable colored compositions, color filters and processes for preparing them, liquid crystal display devices, solid-state image sensors, and dye compounds | FUJIFILM CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8754233-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8410272-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1542997-B1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA CANADA INC (CA) | 2012-02-29 | — | — | EP | disclosed |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Valocor Therapeutics, Inc. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-7847101-B2 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | Valocor Therapeutics, Inc. (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | disclosed |
| EP-1542997-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, Inc. (CA) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004011460-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, INC. (CA) | 2004-02-05 | — | — | WO | disclosed |
| US-4268668-A | FOR WOOL AND POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-19 | — | — | US | disclosed |
| US-4249010-A | FOR POLYESTERS; COLORFASTNESS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-03 | — | — | US | disclosed |
| US-4201713-A | COLORFASTNESS | BAYER AKTIENGESELLSCHAFT (DE) | 1980-05-06 | — | — | US | disclosed |
| US-4097484-A | ORGANIC PIGMENTS, PLASTICS | CIBA-GEIGY CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
| US-4002635-A | FOR COLORING PLASTICS AND LACQUERS | CIBA-GEIGY CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | TST, PTK2, PTK2B | CYP1A2 4050/4885CYP3A4 3466/4885CYP2C19 3358/4885 |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | REN, PGF, PKD1 | CYP1A2 892/4885CYP3A4 1466/4885CYP2C19 580/4885 |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | CYP1A2 96/4885CYP3A4 120/4885CYP2C19 111/4885 |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | CYP1A2 96/4885CYP3A4 120/4885CYP2C19 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.